PD-L1, in particular, is a widely studied predictive biomarker for immune checkpoint inhibitors (ICIs) across cancers, including bladder cancer, where its high expression is associated with advanced pathological stage and better response to therapies like pembrolizumab and atezolizumab (27, 28). Here, CD274 is linked to urinary bladder cancer.